Gemcitabine Injection, 1 g recall — Mckesson (Class II)

Mckesson is recorded by the U.S. Food and Drug Administration (FDA) as recalling Gemcitabine Injection, 1 g — a Class II recall, initiated 2026-06-10 and posted to the FDA enforcement report on 2026-07-08, under recall number D-0714-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.”. From the product description, the form is injection, the strengths given are 1 g, 26.3 mL, 38 mg/mL and 38690 G and it is marked Rx only. 1 National Drug Code number is printed in the record: 0143-9341-01. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in TX, United States. It is the only recall number the FDA has filed under event ID 99262. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0714-2026
FDA event ID 99262
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Mckesson
Recall initiated 2026-06-10
Reported by FDA 2026-07-08
Report lag 28 days from initiation to report
Distribution Nationwide within the United States — Nationwide (US)
Firm location on record TX, United States
Product description (source) Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01

Reason reported by FDA

Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

17 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

9 identifying values matched by exact pattern in the 38-word product description above; each is a literal substring of it.

Product named Gemcitabine Injection
Form Injection
Strength 1 g · 26.3 mL · 38 mg/mL · 38690 G
NDC 0143-9341-01
Marketing category Rx only
Manufactured by THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23
Distributed by Hikma, Berkeley Heights

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
BD ChloraPrep Hi-Lite Orange, 2%D-0643-2026Carefusion 213, LLCClass II2026-07-08
BD PurPrep, 8.3%D-0644-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Clear, 2%D-0645-2026Carefusion 213, LLCClass II2026-07-08
ChloraPrep FREPP, 2%D-0646-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Hi-Lite Orange, 2%D-0647-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Hi-Lite Orange, 2%D-0648-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Scrub Teal, 2%D-0649-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Scrub Teal, 2%D-0650-2026Carefusion 213, LLCClass II2026-07-08

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-07-08 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
BD ChloraPrep CLear, 2%D-0651-2026Carefusion 213, LLC2% · Solution2026-07-08
BD ChloraPrep CLear, 2%D-0652-2026Carefusion 213, LLC2% · Solution2026-07-08
IMULDOSA, 130 mg/26 mLD-0653-2026Accord Biopharma Inc130 mg/26 mL · Injection2026-07-08
prednisoLONE Acetate Ophthalmic Suspension, 1%D-0655-2026Lupin Pharmaceuticals Inc.1% · Ophthalmic Suspension2026-07-08
Levothyroxine Sodium Tablets, 300 mcgD-0656-2026Accord Healthcare, Inc.300 mcg · Tablets2026-07-08
Synjardy XR Tablets, 1000 mgD-0657-2026Boehringer Ingelheim Pharmaceuticals, Inc.1000 mg · Extended-Release Tablets2026-07-08
Accucaine, 1%D-0658-2026Asclemed Usa Inc.1% · Injection2026-07-08
Lidocaine HCl Injection USP, 1%D-0659-2026Asclemed Usa Inc.1% · Injection2026-07-08

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 0143-9341-01 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Mckesson (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0714-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0714-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-08
Ingested
2026-08-22
Record hash
d6be6c16772b10d0

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.